BRPI0706575B8 - uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado. - Google Patents
uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.Info
- Publication number
- BRPI0706575B8 BRPI0706575B8 BRPI0706575A BRPI0706575A BRPI0706575B8 BR PI0706575 B8 BRPI0706575 B8 BR PI0706575B8 BR PI0706575 A BRPI0706575 A BR PI0706575A BR PI0706575 A BRPI0706575 A BR PI0706575A BR PI0706575 B8 BRPI0706575 B8 BR PI0706575B8
- Authority
- BR
- Brazil
- Prior art keywords
- collagen
- type
- autoimmune response
- sample
- lung
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000012432 Collagen Type V Human genes 0.000 title abstract 3
- 108010022514 Collagen Type V Proteins 0.000 title abstract 3
- 210000000056 organ Anatomy 0.000 title abstract 3
- 210000004072 lung Anatomy 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 title 1
- 238000002054 transplantation Methods 0.000 title 1
- 208000019693 Lung disease Diseases 0.000 abstract 5
- 230000006472 autoimmune response Effects 0.000 abstract 5
- 102000008186 Collagen Human genes 0.000 abstract 4
- 108010035532 Collagen Proteins 0.000 abstract 4
- 229920001436 collagen Polymers 0.000 abstract 4
- 210000001519 tissue Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- 241000486679 Antitype Species 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 abstract 1
- 230000003367 anti-collagen effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 abstract 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rehabilitation Therapy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75919506P | 2006-01-13 | 2006-01-13 | |
| US60/759195 | 2006-01-13 | ||
| PCT/US2007/060533 WO2007120947A1 (en) | 2006-01-13 | 2007-01-13 | Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0706575A2 BRPI0706575A2 (pt) | 2011-04-05 |
| BRPI0706575B1 BRPI0706575B1 (pt) | 2018-12-11 |
| BRPI0706575B8 true BRPI0706575B8 (pt) | 2021-05-25 |
Family
ID=38609836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0706575A BRPI0706575B8 (pt) | 2006-01-13 | 2007-01-13 | uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7759075B2 (https=) |
| EP (2) | EP2672266B1 (https=) |
| JP (2) | JP5030973B2 (https=) |
| CN (1) | CN101375157B (https=) |
| AU (1) | AU2007238533C1 (https=) |
| BR (1) | BRPI0706575B8 (https=) |
| CA (2) | CA2641318C (https=) |
| WO (1) | WO2007120947A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2672266B1 (en) * | 2006-01-13 | 2018-08-01 | Indiana University Research & Technology Corporation | Method for screening a lung transplant candidate for an elevated risk of rejection |
| US20100172886A1 (en) * | 2006-11-28 | 2010-07-08 | University Of Southern California | Method for Promoting Wound Healing |
| EP2395996A1 (en) * | 2009-02-13 | 2011-12-21 | Indiana University Research and Technology Corporation | Compounds and methods for inhibiting mmp2 and mmp9 |
| ES2618881T3 (es) * | 2009-04-22 | 2017-06-22 | Indiana University Research And Technology Corporation | Colágeno V para su uso en el tratamiento del asma |
| JP2013509883A (ja) | 2009-11-06 | 2013-03-21 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 臓器移植患者における移植片拒絶反応の非侵襲的診断方法 |
| AU2012262154B2 (en) * | 2011-05-31 | 2016-08-04 | Idexx Laboratories, Inc. | Detection of degradation products of feline NT-proBNP |
| CN107099581B (zh) * | 2012-03-27 | 2021-07-13 | 弗·哈夫曼-拉罗切有限公司 | 预测、诊断和治疗特发性肺纤维化的方法 |
| JP6058354B2 (ja) * | 2012-11-02 | 2017-01-11 | 東芝メディカルシステムズ株式会社 | 画像処理装置及び画像処理方法 |
| JP6312054B2 (ja) * | 2013-11-06 | 2018-04-18 | 学校法人日本大学 | 間質性肺炎のバイオマーカー |
| US20170082619A1 (en) | 2015-09-23 | 2017-03-23 | One Lambda, Inc. | Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444879A (en) * | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
| DE69133095T2 (de) | 1990-11-20 | 2003-03-27 | Dade Behring Marburg Gmbh | Cyclosporin-Immunoassay |
| US6911220B1 (en) | 1992-02-19 | 2005-06-28 | The General Hospital Corporation | Allogeneic and xenogeneic transplantation |
| JP2702354B2 (ja) * | 1992-05-11 | 1998-01-21 | 帝人株式会社 | 血中の肺組織障害マーカー |
| US5778875A (en) * | 1996-05-06 | 1998-07-14 | U.S. Divers Co., Inc. | First stage regulator and rotatable in-line valve |
| AUPO026596A0 (en) * | 1996-06-05 | 1996-06-27 | Biomolecular Research Institute Limited | Viral peptide |
| US5962025A (en) | 1996-07-16 | 1999-10-05 | The University Of Tennessee Research Corporation | Method for treatment of systemic sclerosis and related fibrotic diseases |
| US5990274A (en) | 1997-11-25 | 1999-11-23 | Dade Behring Inc. | Cyclosporine derivatives and uses thereof |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| AU2001230531A1 (en) * | 2000-01-31 | 2001-08-14 | Asahi Kasei Kabushiki Kaisha | Antibody for detecting chlamydia pneumoniae |
| US7348005B2 (en) | 2000-03-15 | 2008-03-25 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
| BR0109455A (pt) * | 2000-03-23 | 2003-06-03 | Akzo Nobel Nv | Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos |
| JP2002220343A (ja) * | 2001-01-26 | 2002-08-09 | Toray Ind Inc | びまん性肺疾患延命剤 |
| JP2007532883A (ja) * | 2004-04-08 | 2007-11-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 組織サンプルにおけるコラーゲンの免疫組織化学的検出方法 |
| US7718765B2 (en) | 2005-11-16 | 2010-05-18 | The University Of Tennessee Research Foundation | Methods of treating fibrosing diseases by induction of immune tolerance |
| EP2672266B1 (en) * | 2006-01-13 | 2018-08-01 | Indiana University Research & Technology Corporation | Method for screening a lung transplant candidate for an elevated risk of rejection |
-
2007
- 2007-01-13 EP EP13175642.1A patent/EP2672266B1/en not_active Not-in-force
- 2007-01-13 EP EP07756361.7A patent/EP1977234B1/en not_active Not-in-force
- 2007-01-13 WO PCT/US2007/060533 patent/WO2007120947A1/en not_active Ceased
- 2007-01-13 CN CN200780003133.2A patent/CN101375157B/zh not_active Expired - Fee Related
- 2007-01-13 AU AU2007238533A patent/AU2007238533C1/en not_active Ceased
- 2007-01-13 JP JP2008550549A patent/JP5030973B2/ja not_active Expired - Fee Related
- 2007-01-13 CA CA2641318A patent/CA2641318C/en active Active
- 2007-01-13 BR BRPI0706575A patent/BRPI0706575B8/pt not_active IP Right Cessation
- 2007-01-13 CA CA2965211A patent/CA2965211C/en active Active
-
2008
- 2008-07-11 US US12/171,661 patent/US7759075B2/en active Active
-
2010
- 2010-06-25 US US12/823,570 patent/US7939281B2/en active Active
-
2011
- 2011-04-07 US US13/082,203 patent/US8039225B2/en active Active
- 2011-12-27 JP JP2011285617A patent/JP5936349B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1977234A1 (en) | 2008-10-08 |
| CA2965211C (en) | 2020-06-30 |
| US7759075B2 (en) | 2010-07-20 |
| CN101375157A (zh) | 2009-02-25 |
| US20110183356A1 (en) | 2011-07-28 |
| EP2672266A3 (en) | 2014-02-05 |
| JP5030973B2 (ja) | 2012-09-19 |
| EP1977234A4 (en) | 2009-06-03 |
| JP2012108137A (ja) | 2012-06-07 |
| US7939281B2 (en) | 2011-05-10 |
| EP2672266B1 (en) | 2018-08-01 |
| CA2965211A1 (en) | 2007-10-25 |
| CA2641318C (en) | 2017-06-20 |
| US20110020838A1 (en) | 2011-01-27 |
| CN101375157B (zh) | 2015-06-17 |
| BRPI0706575B1 (pt) | 2018-12-11 |
| US20090017013A1 (en) | 2009-01-15 |
| JP2009524023A (ja) | 2009-06-25 |
| EP1977234B1 (en) | 2015-11-04 |
| US8039225B2 (en) | 2011-10-18 |
| CA2641318A1 (en) | 2007-10-25 |
| EP2672266A2 (en) | 2013-12-11 |
| HK1126861A1 (en) | 2009-09-11 |
| AU2007238533B2 (en) | 2012-09-20 |
| WO2007120947A1 (en) | 2007-10-25 |
| AU2007238533C1 (en) | 2013-08-15 |
| BRPI0706575A2 (pt) | 2011-04-05 |
| AU2007238533A1 (en) | 2007-10-25 |
| JP5936349B2 (ja) | 2016-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0706575B8 (pt) | uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado. | |
| JP7849400B2 (ja) | 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法 | |
| Jaffar et al. | Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis | |
| Humblet et al. | Acute phase proteins assessment for an early selection of treatments in growing calves suffering from bronchopneumonia under field conditions | |
| BRPI0619748B8 (pt) | anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste | |
| Ludvigsen et al. | Göttingen minipig model of diet-induced atherosclerosis: influence of mild streptozotocin-induced diabetes on lesion severity and markers of inflammation evaluated in obese, obese and diabetic, and lean control animals | |
| Wood et al. | Accelerated onset of chronic wasting disease in elk (Cervus canadensis) vaccinated with a PrPSc-specific vaccine and housed in a prion contaminated environment | |
| BRPI0509419A (pt) | método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio | |
| Lemberger et al. | Comparison of urine protein profiles in cats without urinary tract disease and cats with idiopathic cystitis, bacterial urinary tract infection, or urolithiasis | |
| Yang et al. | IL-1β–dependent extravasation of preexisting lung-restricted autoantibodies during lung transplantation activates complement and mediates primary graft dysfunction | |
| Kushima et al. | Two cases of pleuroparenchymal fibroelastosis diagnosed with transbronchial lung biopsy | |
| Sousse et al. | Pulmonary histopathologic abnormalities and predictor variables in autopsies of burned pediatric patients | |
| Park et al. | Remote ischemic preconditioning in hemodialysis: a pilot study | |
| US20190041407A1 (en) | Devices, systems and methods for quantifying hemoglobin s concentration | |
| Palladini et al. | Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia | |
| WO2012165926A3 (ko) | 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
| FR3058143A1 (fr) | Nanocorps anti-tau | |
| CN118973710A (zh) | 用于测定血液样品中的uch-l1、gfap和其他生物标志物的系统和方法 | |
| Bartsch et al. | A novel approach to studying infective endocarditis: Ultrasound-guided wire injury and bacterial challenge in mice | |
| Bishop et al. | Reference intervals for equine fecal calprotectin and calprotectin: protein ratio and preliminary clinical evaluation in horses with colic and colitis | |
| Clarke | Exploring the Role of Extracellular Vesicles in Equine Musculoskeletal Pathologies and Associated Regenerative Therapies | |
| US20240067717A1 (en) | Diagnosis and treatment of primary graft dysfunction following lung transplant | |
| Fragni | Identification of novel readouts to assess anti-fibrotic efficacy of new compounds in a bleomycin-induced pulmonary fibrosis mouse model | |
| BRPI0610267B8 (pt) | métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método | |
| Williams | Characterization of muscle tissue in sepsis induced mouse models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/12/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B15V | Prolongation of time limit allowed | ||
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2809 DE 05-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |